Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 Combined With GAP Regimen as Conversion Therapy for Locally Advanced Gallbladder Cancer
NCT07767994Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2026
- Primary completion
- Jun 2028
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in gallbladder cancer, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: R0 Resection Rate at 6 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
gallbladder cancer
Beyond the preview
Go deeper on NCT07767994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07767994.